title: The free beta-subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma.
abstract: The free beta-subunit of human chorionic gonadotropin beta is expressed in several nontrophoblastic tumours and this is usually associated with aggressive disease. Little is known about human chorionic gonadotropin beta expression in renal cancer. We determined the pretreatment levels of human chorionic gonadotropin beta in serum of patients with renal cell carcinoma, and studied whether elevated levels predicted the clinical outcome. Serum samples were collected before surgery from 177 patients with renal cell carcinoma and from 84 apparently healthy controls. Human chorionic gonadotropin beta in serum was measured by a highly sensitive time-resolved immunofluorometric assay. The prognostic value of human chorionic gonadotropin beta, and of usual clinical and pathological variables was analyzed by the Kaplan-Meier method, the log rank test and Cox multiple hazard regression. The serum concentrations of human chorionic gonadotropin beta were increased in 23% of the renal cell carcinoma patients and they were significantly higher in patients with renal cell carcinoma than in controls (P<0.0001). The concentrations did not correlate with clinical stage and histopathological grade, but patients with increased human chorionic gonadotropin beta levels had significantly shorter survival time than those with levels below the median (cut-off 1.2 pmol l(-1), P=0.0029). In multivariate analysis human chorionic gonadotropin beta, tumour stage and grade were independent prognostic variables. The serum concentration of human chorionic gonadotropin beta is an independent prognostic variable in renal cell carcinoma. The preoperative value of human chorionic gonadotropin beta in serum may be used to identify patents with increased risk of progressive disease.
authors.affiliation: Department of Clinical Chemistry, Helsinki University Central Hospital, Biomedicum Helsinki, Rm A418a Haartmaninkatu 8, FIN-00029, Helsinki, Finland. kristina.hotakainen@hus.fi
authors.forename: K
authors.initials: K
authors.lastname: Hotakainen
authors.forename: B
authors.initials: B
authors.lastname: Ljungberg
authors.forename: A
authors.initials: A
authors.lastname: Paju
authors.forename: T
authors.initials: T
authors.lastname: Rasmuson
authors.forename: H
authors.initials: H
authors.lastname: Alfthan
authors.forename: U-H
authors.initials: UH
authors.lastname: Stenman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000473:pathology*; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000096:biosynthesis* / Q000097:blood; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012044:Regression Analysis; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D018997:Chorionic Gonadotropin, beta Subunit, Human